Literature DB >> 10790752

Microglia dysfunction in schizophrenia: an integrative theory.

N A Munn1.   

Abstract

Schizophrenia is a devastating illness of unknown etiology. It is characterized by increased brain ventricular volume, suggesting a progressive neurodevelopmental condition. There is evidence suggesting a correlation between in utero viral exposure and subsequent occurrence of schizophrenia. Many neurotransmitter systems have been implicated as being dysfunctional in schizophrenia. There are also data suggesting immune system dysfunction in schizophrenia, and a negative correlation between schizophrenia and rheumatoid arthritis. Microglia are phagocytic immune cells in the central nervous system (CNS) derived from peripheral blood monocytes. They are involved in brain development, neuroproliferative and neurodegenerative activities, several CNS illnesses, and CNS viral immunity. They may also be involved in neurotransmitter regulation. The current theory postulates microglial dysfunction initiated by early CNS viral exposure results in the abnormal neural development and neurotransmitter dysfunction seen in schizophrenia. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790752     DOI: 10.1054/mehy.1999.0018

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

1.  Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation.

Authors:  Xiaoming Hu; Hui Zhou; Dan Zhang; Sufen Yang; Li Qian; Hung-Ming Wu; Po-See Chen; Belinda Wilson; Hui-Ming Gao; Ru-band Lu; Jau-Shyong Hong
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-26       Impact factor: 4.147

2.  Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach.

Authors:  Anna Fila-Danilow; Krzysztof Kucia; Malgorzata Kowalczyk; Aleksander Owczarek; Monika Paul-Samojedny; Paulina Borkowska; Renata Suchanek; Jan Kowalski
Journal:  Mol Biol Rep       Date:  2012-04-24       Impact factor: 2.316

3.  Microglia are essential to masculinization of brain and behavior.

Authors:  Kathryn M Lenz; Bridget M Nugent; Rachana Haliyur; Margaret M McCarthy
Journal:  J Neurosci       Date:  2013-02-13       Impact factor: 6.167

Review 4.  Microglial activation and progressive brain changes in schizophrenia.

Authors:  L E Laskaris; M A Di Biase; I Everall; G Chana; A Christopoulos; E Skafidas; V L Cropley; C Pantelis
Journal:  Br J Pharmacol       Date:  2016-01-08       Impact factor: 8.739

Review 5.  From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.

Authors:  O D Howes; P Fusar-Poli; M Bloomfield; S Selvaraj; P McGuire
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Sexual differentiation of the rodent brain: dogma and beyond.

Authors:  Kathryn M Lenz; Bridget M Nugent; Margaret M McCarthy
Journal:  Front Neurosci       Date:  2012-02-21       Impact factor: 4.677

Review 7.  Bidirectional Microglia-Neuron Communication in Health and Disease.

Authors:  Zsuzsanna Szepesi; Oscar Manouchehrian; Sara Bachiller; Tomas Deierborg
Journal:  Front Cell Neurosci       Date:  2018-09-27       Impact factor: 5.505

8.  Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair.

Authors:  Anat London; Merav Cohen; Michal Schwartz
Journal:  Front Cell Neurosci       Date:  2013-04-08       Impact factor: 5.505

9.  Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication.

Authors:  Andrea Schmitt; Thomas Bertsch; Heike Tost; Andrea Bergmann; Uwe Henning; Ansgar Klimke; Peter Falkai
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

10.  PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia.

Authors:  M A Di Biase; A Zalesky; G O'keefe; L Laskaris; B T Baune; C S Weickert; J Olver; P D McGorry; G P Amminger; B Nelson; A M Scott; I Hickie; R Banati; F Turkheimer; M Yaqub; I P Everall; C Pantelis; V Cropley
Journal:  Transl Psychiatry       Date:  2017-08-29       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.